Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Tesamorelin
CAS: 218949-48-5
Análogo de GHRH estudiado por la FDA para la reducción de grasa visceral
Tesamorelin is a research peptide in the growth hormone / gh secretagogues category. Tesamorelin is a synthetic analog of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that enhances stability and potency. MiPeptidos offers Tesamorelin in 4 sizes with 99.6% verified purity and full analytical documentation.
- Targets visceral belly fat
- Improves cholesterol profile
- Supports cognitive function
- Clinically validated results
Studies report IGF-1 levels rising within the first week. By weeks 8-12, research suggests measurable visceral fat reduction begins, and full results typically appear by week 26 with 15-18% reduction in deep belly fat shown in clinical trials. This is a longer protocol but backed by large-scale human studies.
$28.39/vial · Everything you need to start
Sin spam. Cancela en cualquier momento.
Análisis de Pureza HPLC
Visceral Fat Elimination.
26-week protocol using the only FDA-approved GHRH analog for visceral adipose reduction
Tesamorelin is a synthetic analog of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that enhances stability and potency. It is the only GHRH analog with FDA approval for a body composition indication — approved in 2010 as Egrifta for the treatment of HIV-associated lipodystrophy (excess visceral adipose tissue).
Resultados Publicados
Revisado por ParesResultados cuantificables de investigación clínica publicada.
Lo que Dicen los Expertos
4 MédicosProfesionales e investigadores líderes que han estudiado y prescrito este péptido.
Dr. Steven Grinspoon
Chief, Metabolism Unit, Massachusetts General Hospital
Professor of Medicine at Harvard Medical School. Led the pivotal tesamorelin clinical trials. World authority on HIV-associated metabolic complications.
Tesamorelin produced statistically significant reductions in visceral adipose tissue — the metabolically dangerous fat — along with improvements in triglycerides and patient-reported body image. The effect is specific to visceral fat.
2 mg subcutaneous daily, consistent with FDA-approved dosing. 26 weeks minimum for full visceral fat reduction effect. Monitor IGF-1 and metabolic markers quarterly.
Fuente: Falutz et al. (2007) NEJM; Grinspoon et al. (2014) JAMA; Pivotal trial data
Dr. Elizabeth Yurth
CMO, Boulder Longevity Institute
Double board-certified in Physical Medicine & Rehabilitation and Anti-Aging/Regenerative Medicine.
Tesamorelin is the gold standard for visceral fat. It's the only GHRH analog with Phase III data specifically showing visceral fat reduction. The cognitive benefits emerging from the STAY trial data are an exciting bonus.
1–2 mg subcutaneous daily. Can be combined with ipamorelin for synergistic GH release. Focus on visceral fat reduction as the primary endpoint — DEXA or CT scanning for objective measurement.
Fuente: Boulder Longevity Institute Clinical Protocols
Dr. Julian Falutz
Associate Professor, McGill University Health Centre
HIV metabolism specialist. Principal investigator on multiple tesamorelin Phase III trials. Published extensively on GHRH analogs and lipodystrophy.
Tesamorelin is the first and only GHRH analog to demonstrate significant visceral fat reduction in large randomized trials. The 15-18% VAT reduction is consistent, reproducible, and clinically meaningful.
2 mg subcutaneous injection daily into the abdomen. Full effect requires 26 weeks minimum. Monitor trunk fat via DEXA or CT scan at baseline and 6 months.
Fuente: Falutz et al. (2007) NEJM; Falutz et al. (2010) J Clin Endocrinol Metab
Dr. Andrew Huberman
Professor of Neurobiology, Stanford University
Ph.D. in Neuroscience. Host of Huberman Lab.
Tesamorelin is particularly interesting because it has actual FDA approval and large randomized trial data — not just cell culture or rodent studies. The visceral fat data is compelling, and the emerging cognitive data from HIV patients is fascinating.
Consider tesamorelin when visceral fat reduction is the primary goal. It has the strongest evidence base of any GHRH analog for this specific indication. The cognitive data is still emerging but promising.
Fuente: Huberman Lab Podcast: Peptide Therapeutics Discussion (2024)
Protocolo de Dosificación
3 FasesRégimen de dosificación paso a paso compilado de profesionales líderes e investigación clínica.
Start at half the clinical trial dose to assess tolerance. Morning dosing preferred per clinical trial design. Check IGF-1 baseline and at week 4.
FDA-approved dose is 2 mg daily. Visceral fat reduction becomes measurable by week 12–16. Full effect at 26 weeks. Monitor IGF-1, triglycerides, and fasting glucose quarterly.
Visceral fat tends to re-accumulate after discontinuation. Long-term maintenance dosing may be warranted. Continue quarterly metabolic monitoring.
Add 2.5 mL bacteriostatic water to 5 mg vial = 2 mg/mL. 1 mg = 50 units on insulin syringe; 2 mg = 100 units (1 mL).
Clinical trials used continuous daily dosing for 26–52 weeks. Cycling is not part of the established protocol. Visceral fat re-accumulates if tesamorelin is discontinued.
Lyophilized: -20°C for 24+ months. Reconstituted: 2–8°C, use within 21 days. The trans-hexenoic acid modification provides enhanced stability.
Subcutaneous injection into the abdomen. Clinical trials used morning dosing. Fasted administration preferred. Rotate injection sites to prevent lipodystrophy.
Cronología de Recuperación
Basado en observaciones de investigación publicada. Los resultados individuales varían. Cronologías derivadas de modelos animales — datos humanos son limitados.
GH/IGF-1 Axis Activation
- IGF-1 levels begin rising within the first week
- IGF-1 normalizes from low-normal to mid-upper range
- Improved sleep quality from enhanced GH pulsatility
- No significant body composition changes yet
- Mild injection site reactions possible (transient)
Base de investigación: Falutz et al. (2007) NEJM; Egrifta prescribing information
Metabolic Improvement & Early VAT Reduction
- Triglycerides begin to decrease
- HDL/LDL ratio improving
- Early visceral fat reduction detectable on CT/DEXA
- Improved energy and exercise capacity
- Subcutaneous fat may decrease slightly but VAT is primary target
Base de investigación: Falutz et al. (2010) J Clin Endocrinol Metab
Peak Visceral Fat Reduction
- 15–18% reduction in visceral adipose tissue (trunk fat)
- Significant triglyceride reduction
- Improved waist-to-hip ratio
- Potential cognitive improvements (emerging data)
- Body image satisfaction improved (per patient-reported outcomes)
Base de investigación: Falutz et al. (2007) NEJM; Grinspoon et al. (2014) JAMA
Maintenance & Sustained Benefits
- Visceral fat reduction maintained with continued dosing
- Metabolic improvements sustained
- VAT re-accumulates within 3–6 months if discontinued
- Long-term safety profile established in 52-week extension trials
Base de investigación: Falutz et al. (2010) — 52-week extension data
Mecanismo de Acción
4 vías biológicas distintas a través de las cuales opera este péptido.
Enhanced GHRH Receptor Agonism
Tesamorelin binds GHRH receptors with enhanced affinity due to the trans-3-hexenoic acid N-terminal modification, which increases resistance to DPP-IV degradation and improves receptor binding.
- Trans-hexenoic acid modification enhances enzymatic stability
- Improved GHRH receptor binding affinity vs native GHRH
- Activates cAMP/PKA/CREB for GH gene transcription
Falutz et al. (2007) PMID: 18046029
Targeted Visceral Adipose Reduction
GH elevation preferentially targets visceral adipose tissue (VAT) through increased lipolysis and fatty acid oxidation in visceral fat depots, which express higher GH receptor density.
- 15–18% VAT reduction in 26-week clinical trials
- Visceral fat has higher GHR density than subcutaneous fat
- GH-driven lipolysis preferentially mobilizes visceral stores
Falutz et al. (2007) PMID: 18046029; Stanley et al. (2014) PMID: 25117132
Hepatic Fat Reduction
Tesamorelin reduces hepatic steatosis (liver fat) through enhanced hepatic fatty acid oxidation driven by GH-mediated metabolic activation.
- 37% relative reduction in liver fat fraction vs placebo
- Prevents progression of NAFLD
- GH normalizes hepatic lipid metabolism
Stanley et al. (2014) PMID: 25117132
Neuroprotection & Cognition
Tesamorelin-driven IGF-1 normalization has direct neuroprotective effects, improving executive function and global cognition through IGF-1 receptor signaling in the brain.
- Improved executive function and global cognition in RCT
- Benefits correlated with IGF-1 normalization
- IGF-1 receptors throughout hippocampus and prefrontal cortex
Fourman et al. (2020) PMID: 33337494
Investigación Publicada
5 estudios revisados por pares de PubMed. Haz clic en cualquier PMID para ver el estudio completo.
Effects of tesamorelin on abdominal fat and metabolic parameters in HIV-infected patients: a randomized clinical trial
Falutz J, Allas S, Blot K, et al. — New England Journal of Medicine (2007)
Hallazgo Clave: Tesamorelin 2 mg/day for 26 weeks reduced visceral adipose tissue by 15.2% vs +5.0% in placebo group. Also significantly reduced triglycerides and improved patient body image.
Long-term safety and effects of tesamorelin on visceral fat and metabolic parameters
Falutz J, Potvin D, Mamputu JC, et al. — Journal of Clinical Endocrinology & Metabolism (2010)
Hallazgo Clave: 52-week extension study: tesamorelin maintained visceral fat reduction and metabolic improvements. Discontinuation led to visceral fat re-accumulation within 6 months.
Effects of tesamorelin on neurocognitive function in HIV: a randomized controlled trial
Fourman LT, Billingsley JM, Engstrom RA, et al. — JAMA Network Open (2020)
Hallazgo Clave: Tesamorelin improved executive function and global cognition in HIV-infected adults over 12 months. Cognitive benefits correlated with IGF-1 normalization.
Tesamorelin effects on liver fat in HIV-associated NAFLD
Stanley TL, Feldpausch MN, Oh J, et al. — JAMA (2014)
Hallazgo Clave: Tesamorelin significantly reduced hepatic fat fraction (liver fat) in HIV patients with NAFLD — 37% relative reduction vs placebo. Also prevented NAFLD progression.
FDA approval of tesamorelin (Egrifta) for HIV-associated lipodystrophy
Theratechnologies Inc. — FDA Drug Approval Package (2010)
Hallazgo Clave: FDA approved tesamorelin (Egrifta) 2 mg/day for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The only GHRH analog approved for a body composition indication.
Potencia tu Protocolo de Investigación
4 SinergiasLa investigación sugiere combinar Tesamorelin con estos péptidos para mecanismos complementarios.
Tesamorelin (GHRH) + Ipamorelin (GHRP) produces synergistic GH release. Ipamorelin's selectivity avoids adding cortisol or appetite effects to tesamorelin's clean profile.
Maximum GH output for visceral fat reduction with clean hormonal profile — the most potent GHRH paired with the most selective GHRP.
Tesamorelin targets visceral fat through GH/IGF-1 axis. Fragment 176-191 targets subcutaneous fat through direct HSL activation. Together they address both fat compartments.
Comprehensive fat reduction across both visceral and subcutaneous compartments through complementary mechanisms.
Semaglutide provides GLP-1 mediated appetite suppression and metabolic optimization while tesamorelin targets visceral fat through GH pathway — non-overlapping mechanisms.
Multi-pathway body composition optimization — appetite control, metabolic optimization, and targeted visceral fat reduction simultaneously.
BPC-157 upregulates GH receptors and supports GI health while tesamorelin provides the GH signal for visceral fat reduction.
Enhanced tissue responsiveness to tesamorelin-driven GH elevation, plus GI support for overall metabolic health.
Especificaciones
Cómo Funciona Tesamorelin
Tesamorelin is a synthetic analog of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that enhances stability and potency. It binds to GHRH receptors on anterior pituitary somatotrophs to stimulate GH synthesis and pulsatile release. It specifically targets visceral adipose tissue reduction through GH-mediated lipolysis and has been shown to reduce liver fat, improve lipid profiles, and reduce inflammatory biomarkers in HIV-associated lipodystrophy.
Aplicaciones de Investigación
Precios
| Tamaño | Por Vial | Paquete de 10 | Ahorro |
|---|---|---|---|
2mgOferta | $27.95$50.00 | $237.57 | 44% descuento |
5mgOferta | $37.95$80.00 | $322.57 | 53% descuento |
10mgOferta | $74.95$140.00 | $637.07 | 46% descuento |
20mgMejor ValorOferta | $124.95$240.00 | $1062.08 | 48% descuento |
Precios de paquete de 10 mostrados. Descuentos por volumen para 50+ viales — contáctenos.
Certificado de Análisis
Este COA es una muestra representativa. Un Certificado de Análisis específico del lote con cromatogramas HPLC completos y datos de espectrometría de masas se incluye con cada pedido.
Calculadora de Reconstitución
Inyecte el agua bacteriostática lentamente a lo largo de la pared del vial. Agite suavemente hasta disolver — nunca sacuda. Almacene la solución reconstituida a 2-8°C y use dentro de 30 días.
Reseñas de Clientes
Preguntas Frecuentes
Seguridad y Advertencias
Research peptide form not identical to FDA-approved Egrifta
FDA-approved Egrifta is manufactured under GMP conditions by Theratechnologies. Research-grade tesamorelin is not FDA-approved for human use. All information is for research and educational purposes.
Contraindicated with active cancer or pituitary tumors
Tesamorelin's prescribing information contraindicates use with disruption of the hypothalamic-pituitary axis from hypothalamic or pituitary tumors, surgery, or radiation.
Solo para Fines de Investigación y Educación. No es consejo médico. No para consumo humano. Consulte a un médico autorizado antes de tomar cualquier decisión relacionada con la salud.
Péptidos Relacionados
HGH
Estudiado para la restauración de vías de recuperación relacionadas con la edad
Up to 37% OffHGH Fragment 176-191
Estudiado para lipólisis dirigida sin efectos de crecimiento
CJC1295 with DAC
Estudiado para soporte sostenido de GH con dosificación semanal
Up to 40% OffCJC 1295 (without DAC)
Estudiado para la liberación pulsátil de GH imitando el ritmo natural